The ADC binds Trop-2 on tumor cells, is internalized, and releases SN-38, which inhibits topoisomerase I to cause DNA damage and apoptosis. Topoisomerase I is the payload’s enzymatic target, not the cell-surface antigen selected by the drug, so topo I–expressing cells are not directly targeted for killing.